



DIASORIN OBTAINS ALL APPROVALS NECESSARY TO COMPLETE THE ACQUISITION OF LUMINEX

Saluggia, July 9, 2021 - DiaSorin S.p.A. (“**DiaSorin**”; FTSE MIB: DIA) announces it has received all approvals necessary to complete the acquisition of Luminex Corporation (“**Luminex**”; NASDAQ: LMNX).

After the approval by Luminex shareholders, and having received all clearances from applicable regulatory authorities, including the Committee on Foreign Investment in the United States (CFIUS), DiaSorin expects the acquisition to close on July 14, 2021.

“Now that we have received the regulatory approvals, the acquisition of Luminex can be completed and this positions DiaSorin as a leading player in the Diagnostics and Life Science space,” commented Carlo Rosa, CEO of DiaSorin. *“I believe that the combination of the talent of DiaSorin and Luminex will create new and innovative solutions for our customers globally.”*

Additional details regarding the contractual terms of the transaction can be found in the press release of April 11, 2021.

For additional information, please contact:

INVESTOR RELATIONS CONTACTS

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39 0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39 0161.487567

emanuela.salvini@diasorin.it

U.S. MEDIA CONTACTS

Mary K. Conway

Tel: +1 516.606.6545

MConway@MKCStrategies.com

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com